A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation

被引：24

作者：

Naccarelli, GV ^{[1
]}

Wolbrette, DL ^{[1
]}

Bhatta, L ^{[1
]}

Khan, M ^{[1
]}

Hynes, J ^{[1
]}

Samii, S ^{[1
]}

Luck, J ^{[1
]}

机构：

[1] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Div Cardiol,Ctr Cardiovasc, Hershey, PA 17033 USA

来源：

JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY | 2003年 / 9卷 / 02期

关键词：

antiarrhythmic drugs; atrial fibrillation;

D O I：

10.1023/A:1026240625182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical trials assessing the efficacy of antiarrhythmic drugs for terminating atrial fibrillation have demonstrated that rate control drugs have little to no added efficacy compared to placebo; however, spontaneous conversion of recent-onset atrial fibrillation is common. Antiarrhythmic drugs such as oral dofetilide, oral bolus-flecainide and propafenone and intravenous ibutilide all have a role in terminating atrial fibrillation. Active comparator trials have demonstrated that amiodarone is more efficacious in maintaining sinus rhythm than propafenone and sotalol. Multiple trials have demonstrated the safety of amiodarone, sotalol, dofetilide and azimilide in a post-myocardial infarction population and amiodarone and dofetilide in a congestive heart failure population. Newer antiarrhythmic agents, some with novel mechanisms of action, will add to the pharmacologic armamentarium in treating atrial fibrillation.

引用

页码：215 / 222

页数：8

共 51 条

[1] Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease - A randomized, controlled trial [J].